SCHEMBL3436232

SCHEMBL3436232

CCOC(=O)c1csc(N2CC=CC2)n1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 7/20 0.55
NPC1 O15118 6/20 0.55
MAPT P10636 5/20 0.55
ALDH1A1 P00352 3/20 0.55
MEN1 O00255 2/20 0.55
KMT2A Q03164 2/20 0.55
GAA P10253 3/20 0.53
CYP1A2 P05177 2/20 0.50
OGA O60502 1/20 0.50
CYP2C19 P33261 1/20 0.50
SMN1; SMN2 Q16637 3/20 0.48
POLB P06746 2/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
LMNA P02545 1/20 0.47
HPGD P15428 1/20 0.47
BLM P54132 1/20 0.47
ESR2 Q92731 1/20 0.47
PKM P14618 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
RXFP1 Q9HBX9 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7185606 0.86 ALDH1A1 (0.62) RAB9ANPC1MAPTALDH1A1MEN1
SCHEMBL10464669 0.84 ALDH1A1 (0.64) RAB9ANPC1MAPTALDH1A1MEN1
SCHEMBL1118526 0.84 OGA (0.54) RAB9ANPC1MAPTALDH1A1MEN1
SCHEMBL10466693 0.83 OGA (0.56) RAB9ANPC1MAPTALDH1A1MEN1
SCHEMBL3555061 0.83 RAB9A (0.52) RAB9ANPC1MAPTALDH1A1MEN1
SCHEMBL5724417 0.83 RAB9A (0.52) RAB9ANPC1MAPTALDH1A1MEN1
SCHEMBL10464496 0.83 OGA (0.53) RAB9ANPC1MAPTALDH1A1MEN1
SCHEMBL5378395 0.82 OGA (0.53) RAB9ANPC1MAPTALDH1A1MEN1
SCHEMBL28518356 0.82 GAA (0.53) RAB9ANPC1MAPTALDH1A1MEN1
SCHEMBL7173774 0.82 OGA (0.55) RAB9ANPC1MAPTALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163746-B2 Azolecarboxamide derivative ASTELLAS PHARMA INC. (JP) 2012-04-24 US disclosed
US-20090286766-A1 AZOLECARBOXAMIDE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2009-11-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286766-A1 AZOLECARBOXAMIDE DERIVATIVE GPR17, NTRK1, TRPV1 RAB9A 4401/4885NPC1 4245/4885MAPT 1330/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.